Campanini 2017.

Trial name or title	Rivaroxaban or placebo for extended antithrombotic prophylaxis after laparoscopic surgery for colorectal cancer: a randomized, double blind, placebo‐controlled study
Methods	Randomized, parallel assignment, triple‐blinded.
Participants	Diagnosis of colorectal cancer (any stage), elective laparoscopic surgery planned.
Interventions	Postoperative LMWH then oral rivaroxaban for 3 weeks versus placebo for 3 weeks.
Outcomes	Composite of symptomatic objectively confirmed VTE, asymptomatic ultrasonography‐confirmed DVT or VTE‐related death.
Starting date	May 3, 2017
Contact information	cecilia.becattini@unipg.it
Notes	Rivaroxaban is a direct Factor Xa inhibitor.

DVT: deep venous thrombosis; LMWH: low molecular weight heparin; VTE: venous thromboembolism.